CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
0.124
-0.003 (-2.52%)
At close: Nov 20, 2024, 4:00 PM
0.128
+0.004 (3.56%)
Pre-market: Nov 21, 2024, 7:35 AM EST
CNS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CNS Pharmaceuticals stock has a target of 0.50, which predicts an increase of 304.53% from the current stock price of 0.12.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 10, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for CNSP is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
---|---|---|---|---|
Strong Buy | 2 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 |
Total | 2 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $0.5 | Hold → Strong Buy | Upgrades | $0.5 | +304.53% | Sep 10, 2024 |
Brookline Capital | Brookline Capital | Strong Buy Initiates $15,000 | Strong Buy | Initiates | $15,000 | +12,135,822.33% | Feb 2, 2021 |
Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $16,500 | Strong Buy | Initiates | $16,500 | +13,349,414.56% | Aug 24, 2020 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.87
from -250.19
EPS Next Year
-0.40
from -0.87
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | n/a | n/a |
Avg | n/a | n/a |
Low | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -0.89 | -0.41 | -0.38 |
Avg | -0.87 | -0.40 | -0.37 |
Low | -0.83 | -0.38 | -0.35 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.